These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 21219987

  • 1. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.
    Vaccine; 2011 Feb 24; 29(10):1921-8. PubMed ID: 21219987
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD, GRC28 Study Team.
    Pediatr Infect Dis J; 2010 Feb 24; 29(2):105-10. PubMed ID: 19934787
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.
    Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L.
    Vaccine; 2006 Mar 06; 24(10):1601-8. PubMed ID: 16303215
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.
    Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle P, Peeters M, Innis BL, Devaster JM.
    J Infect Dis; 2009 Dec 15; 200(12):1861-9. PubMed ID: 19909082
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B, CAIV-T Asthma Study Group.
    Pediatr Infect Dis J; 2006 Oct 15; 25(10):860-9. PubMed ID: 17006278
    [Abstract] [Full Text] [Related]

  • 6. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 15; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 7. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.
    Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M.
    Vaccine; 2011 Oct 13; 29(44):7733-9. PubMed ID: 21835220
    [Abstract] [Full Text] [Related]

  • 8. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z.
    Vaccine; 2004 Jun 30; 22(20):2566-77. PubMed ID: 15193382
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
    Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M.
    N Engl J Med; 2006 Mar 30; 354(13):1343-51. PubMed ID: 16571878
    [Abstract] [Full Text] [Related]

  • 10. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ, Gussekloo J, Remmerswaal JE, Remarque EJ, Kroes AC.
    J Med Virol; 2009 May 30; 81(5):908-14. PubMed ID: 19319953
    [Abstract] [Full Text] [Related]

  • 11. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 30; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.
    Clin Infect Dis; 2009 Apr 15; 48(8):1087-95. PubMed ID: 19281330
    [Abstract] [Full Text] [Related]

  • 13. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
    Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW, Treanor JJ, Walter Reed Health Care System Influenza Vaccine Consortium.
    Arch Intern Med; 2008 Dec 08; 168(22):2405-14. PubMed ID: 19064822
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.
    Morelon E, Pouteil Noble C, Daoud S, Cahen R, Goujon-Henry C, Weber F, Laurent PE, Kaiserlian D, Nicolas JF.
    Vaccine; 2010 Oct 04; 28(42):6885-90. PubMed ID: 20709000
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D.
    J Infect Dis; 2006 Oct 15; 194(8):1032-9. PubMed ID: 16991077
    [Abstract] [Full Text] [Related]

  • 16. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
    Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M.
    N Engl J Med; 1998 May 14; 338(20):1405-12. PubMed ID: 9580647
    [Abstract] [Full Text] [Related]

  • 17. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD, CAIV-T Study Group.
    Pediatr Infect Dis J; 2006 Oct 14; 25(10):870-9. PubMed ID: 17006279
    [Abstract] [Full Text] [Related]

  • 18. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
    Lambkin-Williams R, Gelder C, Broughton R, Mallett CP, Gilbert AS, Mann A, He D, Oxford JS, Burt D.
    PLoS One; 2016 Oct 14; 11(12):e0163089. PubMed ID: 28005959
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
    Glenn GM, Thomas DN, Poffenberger KL, Flyer DC, Ellingsworth LR, Andersen BH, Frech SA.
    Vaccine; 2009 Dec 30; 27 Suppl 6():G60-6. PubMed ID: 20006142
    [Abstract] [Full Text] [Related]

  • 20. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, Al-Ibrahim MS, Kabongo ML, Steigbigel R, Belshe RB, Kitt ER, Chu AH, Moss RB.
    Vaccine; 2010 Mar 16; 28(13):2565-72. PubMed ID: 20117262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.